Review of Biologic Therapies

REFERENCES

• Savage C, St. Clair EW. New therapeutics in rheumatoid arthritis. Rheum Dis Clin North Am 2006;32:57–74.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. New Eng J Med 2004;350:2167–2179.
   PubMed Web of Science ®Google Scholar
• Firestein. Kelley’s textbook of rheumatology, 8th ed. 2008. Online edition.
   Google Scholar
• Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. New Eng J Med 2006;355:704–712.
   PubMed Web of Science ®Google Scholar
• Pucino Jr. F, Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: Where are we going? Am J Health-Syst Pharm 2006;63(4):S19–S41.
   Google Scholar
• Johnston SL. Biologic therapies: What and when? J Clin Pathol 2007;60:8–17.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Li Ju, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with lnfliximab. Ann Intern Med 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009;35:183–199.
   PubMed Web of Science ®Google Scholar
• Saketkoo L, Espinoza LR. Impact of biologic agents on infectious diseases. Infectious Disease Clinics of North America 2006;20:931–961.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson E, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systemic reviewand meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–2285.
   PubMed Web of Science ®Google Scholar
• Guthrie B, Rouster-Stevens KA, Reynolds SL. Review of medications used in juvenile rheumatoid arthritis. Pediatric Emergency Care 2007;23(1):38–46.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen S, Moerland L, Lium D, Robbins S, Newmark R, Bekker P. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412–1419.
   PubMed Web of Science ®Google Scholar
• Fleishmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHulL-1ra), placebo-controlled trial.. Arthritis Rheum 2003;48:927–934.
   PubMed Web of Science ®Google Scholar
• Sweet BV. Abatacept. Am J Health-Syst Pharm 2006;63(1):2065–2077.
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KGC, Savage COS, Jayne DRW. A Multicenter Survey of Rituximab Therapy for Refractory Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.. Arthritis Rheum 2009;60(7):2156–2168.
   PubMed Web of Science ®Google Scholar
• Kurz PA, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: A series of four cases.. Br J Ophthalmol 2009;93:546–548.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox R, Wingerchuk D, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BAC. Treatment of neuromyelitis optica with rituximab.. Arch Neurol 2008;65:1443–1448.
   PubMed Web of Science ®Google Scholar
• Pesocovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006;6:859–866.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Bouaziz JD, Matsüshita T, Margo CM, St.Clair Ew, Tedder TF. B-lymphocyte contributions to human autoimmune disease.. Immunological Reviews. 2008;223:284–299.
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study.. Arthritis Rheum 2008;58:964–975.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Lareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. GO-FORWARD study. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutanesou injections, ikn active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study.. Ann Rheum Dis 2009;68(6):789–796.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mclnnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.. Arthritis Rheum 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvantahan S, Xu Z. Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial.. Arthritis Rheum 2008;58:3402–3412.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman Mu, Baker D, Mascelli MA, Davis HM, Everitt DE. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonoal antibody, in subjects with rheumatoid arthritis.. J Clin Pharmacol 2007;47:383–396.
   PubMed Web of Science ®Google Scholar
• Simponi.com [Internet]. Centocor Ortho Biotech, Inc. [updated 2009 Jun 12; cited 2009 Aug 31]. Available from: http://www.simponi.com
   Google Scholar
• Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial.. Ann Rheum Dis 2009;68:797–804.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, lnnes A, Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study.. Ann Rheum Dis 2009;68:805–811.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study.. Arthritis Rheum 2008;58:3319–3329.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn’s disese.. New Eng J Med 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rugeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, lnnes A. CDP870 Crohn’s Disease Study Group. A randomized, placebo-controled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease.. Gasteroenterology 2005;129:807–818.
   PubMed Web of Science ®Google Scholar
• Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn’s disease: Focus on certolizumab pegol.. Int J Nanomedicine. 2007;2(1):39–47.
   PubMed Web of Science ®Google Scholar
• Nesbitt AM, Henry AJ. High affinity and potency of the pegylated Fab’ fragment CDP870—a direct comparison with other anti-TNF agents. Am J Gastroenterol 2004;99Suppl 10:S253. Abstract.
   Web of Science ®Google Scholar
• Fosatti G, Nesbitt AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated perpiheral blood lymphocytes and monocytes.. Am J Gastroenterol 2005;Suppl 9;S298–299. Abstract.
   Google Scholar
• Fosatti G, Nesbitt AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, inflixicmab, and certolizumab pegol (CDP870). Am J Gastroenterol 2005;100Suppl 17:S200. Abstract.
   Google Scholar
• Scott DL, Cope A. New tumour necrosis factor inhibitors for rheumatoid arthritis: Are there benefits from extending choice? Ann Rheum Dis 2009:68(6);767–769.
   PubMed Web of Science ®Google Scholar
• Cimzia.com [Internet]. UCB, Inc; 2009 [accessed 31 August 2009]. Available from: http://www.cimzia.com.
   Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC. Thomsen OO, Hanauer SB. McColm J, Bloomfield R, Sandborn WJ. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Cronn’s disease.. N Engl J Med 2007:357:239–250.
   PubMed Web of Science ®Google Scholar
• Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnany outcomes in women with rheumatic diseases.. Arthritis Rheum 2009;61:587–592.
   PubMed Web of Science ®Google Scholar
• Stephens S, Nesbitt A, Foulkes R. Comparison of placental transfer of Ig G1 and P E Gylated Fab’ version of the anti-TNF antibody T N3 in rats: Potential implications for anti-TNF agents.. Arthritis Rheum 2006;54:S351. Abstract.
   Google Scholar
• Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Tocilizumab.. Nat Rev Drug Discov 2009;8(4):273–274.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T. Miyoshi M. Tomiita M. Nishimoto N. Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial.. Lancet 2008;371(9617):998–1006.
   PubMed Web of Science ®Google Scholar
• Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.. Arthritis Res 2005;7(6):R1281–1288.
   Google Scholar
• Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years.. Mod Rheumatol 2009;19(1):69–72.
   PubMed Web of Science ®Google Scholar
• Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, Hirano T, Narazaki M, Ogata A, Yoshizaki K, Kawase I, Kishimoto T, Tanaka T. Improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment.. Ann Rheum Dis 2009;68:1235–1236.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54(9):2997–3000.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.. Arthritis Rheum 2008;58(4):1197–1200.
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease.. Intern Med 2007;46(11):771–774.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial.. Ann Rheum Dis 2008,67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K. Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T. CHARISMA Study Group.. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate Arthritis Rheum 2006;54(9):2817–2829.
   Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.. Mod Rheumatol 2009;19(6):12–19.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial.. Lancet 2008;371(9617):987–997.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab.. Ann Rheum Dis 2007;66(9):1162–1167.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.. Arthritis Rheum 2008;58(10):2968–2980.
   PubMed Web of Science ®Google Scholar
• Roactemra.com [Internet]. Hoffman-La Roche Ltd; [Accessed 31 August 2009]. Available from: http://www.roactemra.com.
   Google Scholar
• Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47(12):1838–1840.
   PubMed Web of Science ®Google Scholar
• Prendiville C, O’Doherty M, Moriarty P, Cassidy L. The use of infliximab in ocular inflammation.. Brit J Ophthal 2008;92:823–825.
   PubMed Web of Science ®Google Scholar
• Tauber T. Daniel D. Barash J. Avni I. Morad Y. Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis.. Rheumatology 2005;44:405.
   PubMed Web of Science ®Google Scholar
• Strong BY, Erny BC, Herzenberg H, Razzeca KJ. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease.. Ann Intern Med 2004;140:W34.
   PubMedGoogle Scholar
• Chung JH. Van Stavern GP, Frohman LP, Turbin R. Adalimumab-associated optic neuritis.. J Neurol Sci 2006;244:133–136.
   PubMed Web of Science ®Google Scholar
• Simsek I, Erdem H, Pay S, Sobaci G. Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.. Ann Rheum Dis 2007;66:1255–1258.
   PubMed Web of Science ®Google Scholar
• Richards JC, Tay-Kearney ML, Murray K. Infliximab for juvenile idiopathic arthirits-associated uveitis. Clin Exp Ophthal 2005;33:461–468.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT. lnfliximab therapy for refractory uveitis: 2-year results of a prospective trial.. Arch Ophthal 2009;127:819–822.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rodevand E, Holck P. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis 2009;68:696–701.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, Udaondo P, Hernández-Garfella M, Bosch-Morell F, Quijada A, Romero FJ. Adalimumab therapy for refractory uveitis: A pilot study.. J Ocul Pharm Ther 2008;24:351–361.
   PubMed Web of Science ®Google Scholar
• Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, Cimaz R. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.. Rheumatology 2008;46:1510–1514.
   Google Scholar
• Ardoin SP, Kredich D, Rabinovich EL, Schanberg, G. Jaffe. lnfliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up.. Amer J Ophthal 2007;144:844–849.
   PubMed Web of Science ®Google Scholar
• Katz JM, Bruno MK, Winterkorn J M, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: A unique therapeutic response to infliximab.. Arch Neurol 2003;60:426–430.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial.. Chest 2005;128:1062–1067.
   PubMed Web of Science ®Google Scholar
• Alabduljalil T, Behbehani R. Paraneoplastic syndromes in neuro-ophthalmology. Curr Opin Ophthal 2007;18:463–469.
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica.. Neurology 2005;64:1270–1272.
   PubMed Web of Science ®Google Scholar